Drugs / Calcium
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ISOPAQUE 280 | — | 1974-04-30 | fda.gov ↗ |
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02338713 | Jan → Feb 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01639222 | Jul → Aug 2012 | calcium metabolic disease, vitamin D deficiency | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00642252 | Jan 2012 → Dec 2013 | dental caries | Indiana Nanotech, LLC | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05691959 | Jan 2023 → Jan 2025 | atrial fibrillation, hypotensive disorder | Ascension Health | Unknown | No outcome recorded |
| Phase 2 | NCT04225767 | Feb 2020 → Jan 2023 | cancer | Zealand University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00973336 | Sep 2009 → Sep 2017 | metabolic bone disorder, primary hyperparathyroidism | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT00000543 | Aug 1993 → Jul 1999 | heart disorder, preeclampsia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00000402 | Aug 1991 → Dec 2001 | osteoporosis | Ohio State University | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05523609 | Nov 2022 → Sep 2024 | breast cancer | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02066688 | Jan 2013 → Dec 2015 | colorectal neoplasm | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT00302276 | Jan → Jul 2004 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 38 trials · 1 met primary | ||||||
| Phase 3 | NCT05612984 | Apr 2024 → Jun 2026 | fetal growth restriction, hypertension, pregnancy-induced | Johns Hopkins Bloomberg School of Public Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT02007837 | Jan → Apr 2018 | hypertension, pregnancy-induced | UMC Utrecht | Unknown | No outcome recorded |
| Phase 3 | NCT01427335 | Oct 2011 → Sep 2013 | ovarian hyperstimulation syndrome | Cairo University | Completed | Met primary |
| Phase 3 | NCT01452243 | Nov 2008 → Nov 2011 | — | Gerencia de Atención Primaria, Albacete | Unknown | No outcome recorded |
| Phase 3 | NCT00172172 | Jan 2004 → Mar 2005 | osteoporosis | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00357643 | Oct 1992 → Feb 1996 | osteoporosis | Tufts University | Completed | No outcome recorded |
| Phase 3 | NCT00000534 | Mar 1991 → Jun 2000 | HELLP syndrome, eclampsia, heart disorder | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 3 | NCT00000611 | ? → Mar 2005 | breast neoplasm, colonic neoplasm, coronary artery disorder, disease of bone structure +2 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Mixed |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT00160264 | Jan 2003 → ? | osteoporosis | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00353054 | Jan 2003 → Jul 2005 | obesity disorder | Laval University | Completed | Missed primary |
| Phase not applicable5 trials | ||||||
| — | NCT07651709 | Jun 2026 → Jan 2035 expected | disease of bone structure, epilepsy | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| — | NCT07381998 | Jan 2026 → Jul 2027 expected | secondary hypoparathyroidism due to impaired parathormon secretion | Aarhus University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT05354310 | Feb 2022 → Feb 2024 | — | Leiden University Medical Center | Unknown | No outcome recorded |
| — | NCT05186194 | Sep 2021 → Jun 2022 | — | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT00567606 | Apr 2002 → Dec 2007 | postmenopausal osteoporosis | University of Nebraska | Completed | No outcome recorded |
| Comparator or background therapy54 trials | ||||||
| Phase 0 | NCT03629717 Background | Jun → Dec 2018 | female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00298545 Comparator | Nov 2005 → May 2009 | adenocarcinoma, colorectal adenoma, polyp | Rockefeller University | Completed | No outcome recorded |
| Phase 2 | NCT04850222 Comparator | Sep 2021 → Feb 2025 | musculoskeletal system disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT04067726 Background | Aug 2019 → Sep 2025 overdue | female breast upper-inner quadrant cancer | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02854722 Background | Jan 2018 → Jun 2019 | postmenopausal osteoporosis | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT02944799 Comparator | Dec 2015 → Dec 2021 | osteoporosis, rheumatoid arthritis | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT02074631 Background | Feb 2015 → Oct 2022 | osteoporosis | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00752557 Comparator | Dec 2008 → Apr 2015 | osteoporosis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00623974 Background | May 2008 → Jun 2010 | — | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00323583 Background | May 2006 → ? | pancreatic adenocarcinoma | Seattle Cancer Treatment and Wellness Center | Unknown | No outcome recorded |
| Phase 2 | NCT00172068 Background | Jan 2002 → Nov 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT01304927 Comparator | Feb 2011 → Dec 2014 | male infertility | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT03396380 Comparator | Jul 2017 → Mar 2018 | female infertility | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT01522521 Background | Feb 2012 → Jan 2015 | osteoporosis | Asahi Kasei Therapeutics Corporation | Completed | Met primary |
| Phase 3 | NCT01656512 Comparator | Oct 2011 → Jan 2014 | osteoporosis | Children's Cancer Hospital Egypt 57357 | Completed | No outcome recorded |
| Phase 3 | NCT01480869 Background | Jul 2011 → Dec 2014 | breast cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | Met primary |
| Phase 3 | NCT01087658 Background | Feb 2010 → Mar 2013 | colorectal neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00824993 Background | Dec 2008 → Apr 2017 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00757393 Background | Sep 2008 → Sep 2015 | osteoporosis | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00404820 Background | Oct 2006 → Dec 2008 | osteoporosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00500409 Comparator | Dec 2005 → Dec 2006 | osteoporosis | Virchow Group | Completed | No outcome recorded |
| Phase 3 | NCT00043719 Background | Jul 2002 → Dec 2007 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 3 | NCT00103740 Background | Apr 2002 → Dec 2003 | bone Paget disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05884372 Comparator | Aug 2023 → Jul 2025 | postmenopausal osteoporosis | Xi'an Honghui Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05630768 Background | Jan 2023 → Jul 2025 | postmenopausal osteoporosis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05203588 Background | Oct 2021 → Oct 2022 | osteoporosis | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02602704 Comparator | Dec 2015 → Oct 2017 | rheumatoid arthritis | Hanyang University | Completed | No outcome recorded |
| Phase 4 | NCT02090400 Background | May 2013 → Jul 2015 | postmenopausal osteoporosis | Instituto Palacios | Completed | No outcome recorded |
| Phase 4 | NCT01709110 Background | Oct 2012 → Jul 2016 | postmenopausal osteoporosis | Eli Lilly and Company | Completed | Met primary |
| Phase 4 | NCT01222026 Comparator | Sep 2010 → Dec 2014 | osteoporosis, primary hyperparathyroidism | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00765687 Comparator | Aug 2008 → May 2012 | metastatic carcinoma in the bone, non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT01578434 Comparator | Nov 2007 → Feb 2009 | rickets | Lady Hardinge Medical College | Completed | No outcome recorded |
| Phase 4 | NCT00668330 Comparator | Apr 2007 → May 2009 | systemic lupus erythematosus | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00460733 Comparator | Mar 2007 → Sep 2011 | — | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00491920 Background | Feb 2007 → Feb 2010 | osteoporosis | University Hospital of North Norway | Completed | No outcome recorded |
| Phase 4 | NCT00869622 Comparator | Jun 2006 → Oct 2012 | disease of bone structure, epilepsy, osteoporosis | Boston VA Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00271713 Comparator | Mar 2006 → Sep 2007 | postmenopausal osteoporosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00303485 Background | Feb 2006 → Jun 2007 | postmenopausal osteoporosis | Hoffmann-La Roche | Completed | Met primary |
| Phase 4 | NCT00616694 Background | Jul 2002 → Dec 2004 | osteoporosis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01882400 Background | May 2001 → Sep 2007 | cystic fibrosis, muscular dystrophy, osteoporosis | Gilles Boire | Completed | No outcome recorded |
| Phase 4 | NCT00860964 Comparator | Feb 1998 → Feb 2003 | osteoporosis | Peking Union Medical College | Completed | No outcome recorded |
| — | NCT07334626 Background | Jan → Jul 2026 overdue | breast cancer, osteoporosis | Benha University | Recruiting | No outcome recorded |
| — | NCT07491601 Background | Jan 2025 → Dec 2028 expected | secondary hypoparathyroidism due to impaired parathormon secretion | Nicolas Schlegel | Recruiting | No outcome recorded |
| — | NCT06022237 Background | Sep 2023 → Aug 2024 | cirrhosis of liver, disease of bone structure | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05392790 Background | May 2022 → Oct 2023 | systemic lupus erythematosus | Cairo University | Completed | No outcome recorded |
| — | NCT05970250 Background | Jan → Apr 2022 | breast cancer, osteoporosis | Cairo University | Completed | No outcome recorded |
| — | NCT04555317 Background | May 2021 → Aug 2025 | female reproductive organ cancer | The Christie NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT05395949 Background | Jan 2019 → Dec 2022 overdue | breast disorder, granulomatous mastitis, psychiatric disorder | Wuhan University | Enrolling by invitation | No outcome recorded |
| — | NCT02274454 Comparator | Nov 2014 → Mar 2015 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01806454 Comparator | Oct 2013 → Nov 2015 | preeclampsia | West China Second University Hospital | Unknown | No outcome recorded |
| — | NCT01141998 Background | Dec 2009 → May 2010 | chronic pancreatitis, malabsorption syndrome | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT00990678 Background | Apr 2008 → Feb 2010 | HIV infectious disease | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT00965562 Comparator | Sep 2000 → Jun 2010 | premenstrual tension | Donaghue Medical Research Foundation | Completed | No outcome recorded |
| — | NCT00536653 Comparator | Oct 1999 → Jan 2007 | osteoporosis | Wirral University Teaching Hospital NHS Trust | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 81 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcium | “The objective of the present study was to investigate the acute and sub-chronic effect of a supplement containing green tea extract, capsaisin, caffeine, tyrosine and calcium...” NCT00302276 ↗79“Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.” NCT05395949 ↗ “Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.” NCT00642252 ↗ “G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.” NCT00567606 ↗ “Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention.” NCT05354310 ↗ “Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.” NCT02007837 ↗ “calcium plus vitamin D (calcium+D) supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)” PMID 19263591 ↗ Mar 2009 “Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro” NCT02274454 ↗ “Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days” NCT00500409 ↗ “Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)” NCT00616694 ↗ “(b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate)” NCT04555317 ↗ |
| Known as | calciprex | “calcium (calciprex®, Marcyrl Pharmaceutical Industries) 1250 mg twice daily” NCT03396380 ↗ |
| Modality | Small molecule | — CHEMBL1200496 ↗ |
| Route | Oral | “oral calcium supplementation” NCT00000534 ↗ |